Key result
Digoxin toxicity affects ~1% of treated CHF patients and requires early recognition and antibody fragments.
Why the study?
How is digoxin toxicity diagnosed and managed in clinical practice?
Design
Review
Authors
Loading...
Supports vigilance for toxicity in digoxin-treated HF; leaves open prospective trials on current incidence and management.
How is digoxin toxicity diagnosed and managed in clinical practice?
Digoxin toxicity remains a clinical diagnosis where blood levels do not always correlate with symptoms, and life-threatening cases require prompt treatment with digoxin-specific antibody fragments.
Ibrahim et al. (2021) conducted a review in Digoxin toxicity. Digoxin-specific antibody fragments (Fab fragments) was evaluated. Digoxin toxicity occurs in approximately 1% of treated congestive heart failure patients and is managed with early recognition and administration of digoxin-specific antibody fragments.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: